Genentech: Tecentriq/Cotellic/Zelboraf Combo Study Meets Primary Endpoint
December 13 2019 - 7:37AM
Dow Jones News
By Colin Kellaher
Roche Holdings AG's (ROG.EB) Genentech unit Friday said a phase
3 study of Tecentriq plus Cotellic and Zelboraf met its primary
endpoint of progression-free survival in a form of the skin cancer
melanoma.
Genentech said the study showed adding Tecentriq to Cotellic and
Zelboraf helped to reduce the risk of disease worsening or death in
people with previously untreated BRAF V600 mutation-positive
advanced melanoma compared to placebo plus Cotellic and
Zelboraf.
The company said the safety profile observed in the study was
consistent with the known safety profiles of the individual drugs,
adding that it plans to discuss the results with health
authorities, including the U.S. Food and Drug Administration and
European Medicines Agency.
Exelixis Inc. (EXEL) discovered Cotellic and is collaborating on
the development of the drug with Genentech as part of a 2006
agreement.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2019 07:22 ET (12:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024